ELIZA

return kwic search for patients with out of >500 occurrences
404916 occurrences (No.41 in the rank) during 5 years in the PubMed. [no cache] 500 found

139) E1912 was a randomized phase 3 trial comparing indefinite ibrutinib plus 6 cycles of rituximab (IR) to 6 cycles of fludarabine, cyclophosphamide, and rituximab (FCR) in untreated younger patients with CLL.

--- ABSTRACT ---

PMID:34407545 DOI:10.1182/blood.2020010146

2021 Blood

* Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib.

- E1912 was a randomized phase 3 trial comparing indefinite ibrutinib plus 6 cycles of rituximab (IR) to 6 cycles of fludarabine, cyclophosphamide, and rituximab (FCR) in untreated younger patients with CLL. We describe measurable residual disease (MRD) levels in E1912 over time and correlate them with clinical outcome. Undetectable MRD rates (<1 CLL cell per 104 leukocytes) were 29.1%, 30.3%, 23.4%, and 8.6% at 3, 12, 24, and 36 months for FCR, and significantly lower at 7.9%, 4.2%, and 3.7% at 12, 24, and 36 months for IR, respectively. Undetectable MRD at 3, 12, 24, and 36 months was associated with longer progression-free survival (PFS) in the FCR arm, with hazard ratios (MRD detectable/MRD undetectable) of 4.29 (95% confidence interval [CI], 1.89-9.71), 3.91 (95% CI, 1.39-11.03), 14.12 (95% CI, 1.78-111.73), and not estimable (no events among those with undetectable MRD), respectively. In the IR arm, patients with detectable MRD did not have significantly worse PFS compared with those in whom MRD was undetectable; however, PFS was longer in those with MRD levels <10-1 than in those with MRD levels above this threshold. Our observations provide additional support for the use of MRD as a surrogate end point for PFS in patients receiving FCR. In patients on indefinite ibrutinib-based therapy, PFS did not differ significantly by undetectable MRD status, whereas those with MRD <10-1 tended to have longer PFS, although continuation of ibrutinib would very likely be necessary to maintain treatment efficacy.

--- ABSTRACT END ---

[
right
kwic]

[frequency of next (right) word to patients with]

(1)14 a	(26)3 PAH	(51)2 IgAn	(76)2 neurological
(2)14 severe	(27)3 PTB	(52)2 MIS-C	(77)2 no
(3)12 COVID-19	(28)3 SB	(53)2 MS,	(78)2 or
(4)10 cancer	(29)3 and	(54)2 PH,	(79)2 pancreatic
(5)10 chronic	(30)3 autonomic	(55)2 TSC	(80)2 pre-existing
(6)8 diabetes	(31)3 clinical	(56)2 UWS	(81)2 prolonged
(7)7 acute	(32)3 dysphagia	(57)2 accuracies	(82)2 psoriasis
(8)6 relapsed	(33)3 epilepsy	(58)2 ankylosing	(83)2 pulmonary
(9)5 AN	(34)3 idiopathic	(59)2 any	(84)2 resected
(10)5 MDD	(35)3 inflammatory	(60)2 cerebellar	(85)2 respiratory
(11)5 T2DM	(36)3 newly	(61)2 community-based	(86)2 rheumatoid
(12)5 advanced	(37)3 recurrent	(62)2 comorbidities	(87)2 schizophrenia
(13)5 lipoedema	(38)3 uncontrolled	(63)2 drug-resistant	(88)2 shared
(14)4 AD	(39)2 16p11.2	(64)2 heart	(89)2 special
(15)4 IBD	(40)2 ALL	(65)2 hemorrhagic	(90)2 spondyloarthritis
(16)4 breast	(41)2 ALS	(66)2 high	(91)2 stage
(17)4 chorea	(42)2 AML	(67)2 high-risk	(92)2 suspected
(18)4 critical	(43)2 ASD	(68)2 known	(93)2 symptomatic
(19)4 low	(44)2 BM	(69)2 locally	(94)2 the
(20)3 ARDS	(45)2 CHB	(70)2 lung	(95)2 these
(21)3 CKD	(46)2 COVID-19,	(71)2 mIDH1	(96)2 treatment-resistant
(22)3 CLL	(47)2 CRC	(72)2 major	(97)2 tuberculosis
(23)3 HGSOC	(48)2 CVDRF	(73)2 metastatic
(24)3 ILD	(49)2 HIV	(74)2 mild
(25)3 MD	(50)2 IIM	(75)2 neurologic

add keyword

--- WordNet output for patients --- Overview of noun patient The noun patient has 2 senses (first 1 from tagged texts) 1. (73) patient -- (a person who requires medical care; "the number of emergency patients has grown rapidly") 2. affected role, patient role, patient -- (the semantic role of an entity that is not the agent but is directly involved in or affected by the happening denoted by the verb in the clause) --- WordNet end ---